

PERSONAL INFORMATION

Dolores Montero Corominas

WORK EXPERIENCE

- January 2009- Present **Head of the Division of Pharmacoepidemiology and Pharmacovigilance**
Agencia Española de Medicamentos y Productos Sanitarios (Spain)
Safety identification, quantification, evaluation, risk management, communication, evaluation of impact of regulatory measures, Director of BIFAP program.
- 2006- 2006 **Head of Pharmacoeconomics**
Ministerio de Sanidad y Consumo (Spain)
- 2000- 2005 **Head of Safety evaluation Unit**
Spanish Agency on Medicines and Medical Devices (Spain)
Evaluation of safety issues
- 1991- 1999 **Pharmacovigilance Assessors**
Instituto de Salud Carlos III (Spain)
- 1987- 1990 **Research fellow**
CSIC, Cajal Institute (Spain)
Basic research on psychopharmacology
- 1985- 1986 **Research fellow**
karolinska institute (Sweden)
Clinical research on psychopharmacology
- 1981- 1984 **Assistant professor in pharmacology**
Universidad de Córdoba (Spain)
teaching, research on hypertension

EDUCATION AND TRAINING

- 2007- 2009 **Technical Assessor**
Spanish Agency on Medicines and Medical Devices (Spain)
Compassionate use, technical reports to the Director
- 1986 **PhD on Medicine**
Facultad de Medicina, Universidad de Córdoba (Spain)
basic research on hypertension
- 2007 **Master Degree on Pharmacoeconomics**
Universidad Pompeu i Fabra (Spain)
- 1975- 1981 **Degree on Medicine**
Universidad Complutense Madrid (Spain)

ADDITIONAL INFORMATION

- Expertise** all fields of pharmacovigilance
- Publications** Montero D, De Abajo FJ.
Clozapina, ¿ser o no ser? Editorial.

Medicina Clínica 99:60-2, 1992.

De Abajo FJ, Montero D, Madurga M, Palop R.
Diferencias regionales en el consumo de amiodarona.
Medicina Clínica 98:799, 1992.

Montero D, Esteban C, De Abajo FJ.
Colaboración Internacional en Farmacovigilancia: OMS y CE.
En: Farmacovigilancia en España. Ed. Instituto de Salud Carlos III pp 115-130, 1992.

De Abajo FJ, Serrano-Castro MA, Montero D, Rayón P, Madurga M, Palop R.
Triazolam Regulatory Measures in Spain.
The Lancet 341:185-186, 1993.

De Abajo FJ, Madurga M, Montero D, Adín J, Palop R.
Trends in supply and use of lipid lowering drugs in Spain, 1983 through 1989.
Therapie 48:145-9, 1993.

Santamaría B, Montero D, Palop R, De Abajo FJ.
Programa de Seguimiento de Clozapina.
Información Terapéutica del Sistema Nacional de Salud 17:145-151, 1993.

Santamaría B, Rayón P, Montero D, De Abajo FJ.
Clozapina: el regreso de un medicamento necesario.
Farmacología del SNC 7:107-112, 1993.

Montero D, Moore N, Coulson R, Zabala JL, De Abajo FJ, Kreft-Jais C, Wigglesworth K, Biron A, Monteagudo JL.
Electronic Transmission of Rapid Alerts in Pharmacovigilance: A pilot EC experiment.
Pharmacoepidemiology and Drug Safety 3:163-167, 1994.

Moore N, Montero D, Coulson R, De Abajo FJ, Kreft-Jais C, Biron A, Palop R.
Communication in Pharmacovigilance.
Pharmacoepidemiology and Drug Safety 3:151-155, 1994.

Moore N, Montero D, Coulson R, De Abajo FJ, Kreft-Jain C, Biron A, Monteagudo JL.
The Single Case Format: proposal for a structured message for the telematic transmission of information on individual case reports in pharmacovigilance.
Pharmacoepidemiology and Drug Safety 3:157-162, 1994.

De Abajo FJ, Alonso MP, Rayón P, Santamaría B, Madurga M, Martín G, Montero D.
Uso de psicofármacos en España, 1985-1994.
En: Farmacoeconomía y Psicofarmacología, Ed Doyma, pp 37-53, 1995.

Montero D, Santamaría B, Rayón P, De Abajo FJ.
Time for less control of clozapine?.
The Lancet, 346: 848-849, 1995.

Rayón P, Serrano MA, Del Barrio H, Alvarez C, Montero D, Madurga M, Palop R, De Abajo FJ.
Hypnotic drug use in Spain: A cross-sectional study based on a network of community pharmacies.
The Annals of Pharmacotherapy, 30: 1092-1100, 1996.

Alonso MP, De Abajo FJ, Martínez J, Montero D, Martín-Serrano G, Madurga M.
Evolución del consumo de antidepresivos en España: Impacto de los inhibidores selectivos de la recaptación de serotonina.
Medicina Clínica, 108: 161-166, 1997.

Rayón P, Montero D, Santamaría B, De Abajo FJ.
Benzodiazepine consumption in Spain.
European Journal of Clinical Pharmacology, 52: 321-323, 1997.

Montero D, Madurga M, Palop R, Martín-Serrano G, De Abajo FJ.
Organization of Spanish Pharmacovigilance in the multinational situation: an overview.
Drug Information Journal 31: 889-893, 1997.

Prieto M, De Abajo FJ, Montero D, Martín-Serrano G, Madurga M, Palop R.
Uso de antihipertensivos en España, 1985-1995.
Medicina Clinica (Barc.) 110:247-253, 1998.

Rayón P, Montero D, Madurga M, De Abajo FJ.
From theory to practice - is it easy? A study with hypnotic drugs. In: Balant LP, Benitez J, Dahl SG, eds, 197-201, European Cooperation in the field of scientific and technical research - Clinical pharmacology in psychiatry: finding the right dose for psychotropic drugs. European Communities, Badajoz, 1998.

Montero D, De Abajo FJ, Coulson R, Biron A, Moore N, Ceinos C, Zinnhobler H.
The EuroScaPE Project. In: Mitchard, M (ed), Electronic communication technologies A practical guide for Healthcare Manufacturers. Interpharm Press Inc. Buffalo: 1998.

De Abajo FJ, García Rodríguez LA, Montero D.
Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.
British Medical Journal 319: 1106-1109, 1999 (Reply: BMJ 2000; 320: 1405)

Del Pino AM, De Abajo FJ, Montero D, Madurga M, Martín Serrano G.
Estudio de la utilización de ticlopidina en oficinas de farmacia de España.
Medicina Clínica (Barc) 2000; 115: 211-213.

De Abajo FJ, García Rodríguez LA, Montero D.
Antidepressant drugs: a potential new drug cause of upper gastrointestinal bleeding.
Digest Liver Dis 2000; 32: 455-7

De Abajo FJ, Montero D, Cachá A. Pharmacovigilance: goals and strategies. Methods and Findings in Experimental and Clinical Pharmacology 2000, 22: 405-407.

Santamaría B, Pérez M, Montero D, Madurga M, de Abajo FJ. Uso of antipsychotic agents in Spain through 1985-2000. Eur Psychiatry 2002; 17:471-6

Montero D, Carvajal A. MedDRA: una terminología para la armonización en materia de medicamentos. ICB digital nº 10, 9 de diciembre de 2002

Gómez-Reino J, Carmona L, Rodríguez-Valverde V, Martín Mola E, Montero D (on behalf of the BIOBADASER Group). Treatment of Rheumatoid Arthritis with tumor necrosis factors inhibitors may predispose to significant increase in tuberculosis. Arthritis & Rheumatism 2003; 48: 2122-2127.

De Abajo FJ, Montero D, Madurga M, García-Rodríguez LA. Acute and clinically relevant hepatic injury: a population-based case-control study. British Journal of Clinical Pharmacology 2004; 58: 71-80

Madurga M, De Abajo FJ, Montero D, Martín-Serrano G. El registro de los medicamentos en el contexto europeo: papel de las agencias reguladoras. Revista de Pediatría de Atención Primaria 2004; 6: 323-343.

García del Pozo J, De Abajo FJ, Carvajal A, Montero D, Madurga M, García del Pozo V. Utilización de ansiolíticos e hipnóticos en España (1995-2002). Revista Española de Salud Pública 2004; 78: 401-409

De Abajo FJ, Meseguer CM, Antiñolo G, García-Rodríguez LA; Montero D, CastilloJR, Torelló J, Labour induction with dinoprostone or oxytocin and postpartum disseminated intravascular coagulation: a hospital-based case-control study. American Journal of Obstetrics and Gynecology 2004; 191:1637-1643.

Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Martín Mola E, Carreño L, Figueroa M. On behalf of the BIOBADASER group. Effectiveness of Recommendations to prevent reactivation of latent tuberculosis infections in patients treated with tumor necrosis factor antagonists. Arthritis and Rheumatism 2005; 52:1766-72.

De Abajo FJ, Montero D, Calvo G. El papel de las agencias reguladoras en la evaluación de la seguridad de los medicamentos: a propósito de los inhibidores selectivos de la recaptación de serotonina. Gaceta Sanitaria, 2005; 19:407-9.

Montero D, Vargas E, Cruz C, Andrés-Trelles F. Nuevo real decreto de acceso a medicamentos bajo circunstancias especiales en España. Medicina Clínica 2009; 133:427-32

Madurga M, Lázaro E, Montero D. El Sistema Español de Farmacovigilancia de vacunas. Medicina Clínica 2012; 138:86

Catalá-López F, Martín-Serrano G, Maciá MA, Montero D. Olmesartán para la prevención o retraso de la nefropatía diabética: algunas consideraciones. Rev Esp Cardiol 2012; 65:678-9

Catalá-López F, Macías Saint-Gerons D, de la Fuente Honrubia C, Montero D. Enfermedad renal crónica progresiva y bloqueo dual del sistema renina-angiotensina-aldosterona. *Prev Med* 2014; 60:136

Requena G, Abbing-Karahagopian V, Huerta C, De Bruin ML, Alvarez Y, Miret M, Hesse U, Gardarsdottir H, Souverein PC, Slattery J, Schenider C, Rottenkolber M, Schmiedl S, Gil M, De Groot MC, Bate A, Ruigómez A, García Rodríguez LA, Johansson S, de Vries F, Montero D, Schlienger R, Reynolds R, Klungel OH, de Abajo FJ. Incidence rates and trends of hip/femur fractures in five European countries: comparison using e-healthcare records databases. *Calcif Tissue Int* 2014, 94:580-9.

Macías D, de la Fuente C, Montero D, Gil M, Andrés-Trelles F, Catalá-López F. Standard and intensive lipid-lowering therapy with statins for the primary prevention of vascular diseases: a population-based study. *Europ J clin Pharmacol.* 2014; 70:99-108

Macías D, Fuente C, Montero D, Catalá-López F. Hepatotoxicidad en pacientes tratados con antagonistas del receptor de la endotelina: revisión sistemática y metaanálisis de ensayos clínicos aleatorizados. *Med Clin* 2014, 142:333-42

Saint-Gerons DM, Honrubia C de L, Montero D, González-Bermejo D, de Andrés-Trelles F, Catalá-López F. Statins use and risk of cataracts: firm conclusions are still far off.

J Cardiovasc Pharmacol Ther. 2015 May;20(3):344-5. doi: 10.1177/1074248414557890. Epub 2014 Dec 3.

Huerta C, Abbing-Karahagopian V, Requena G, Oliva B, Alvarez Y, Gardarsdottir H, Miret M, Schneider C, Gil M, Souverein PC, De Bruin ML, Slattery J, De Groot MC, Hesse U, Rottenkolber M, Schmiedl S, Montero D, Bate A, Ruigomez A, García-Rodríguez LA, Johansson S, de Vries F, Schlienger RG, Reynolds RF, Klungel OH, de Abajo FJ. Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project.

Pharmacoepidemiol Drug Saf. 2016 Mar;25 Suppl 1:56-65. doi: 10.1002/pds.3825. Epub 2015 Jul 7.

Macías Saint-Gerons D, de la Fuente Honrubia C, González Bermejo D, Montero D, Gil MJ, Salvador Sanz A, de Andrés-Trelles F, Catalá-López F. [Clinical-Epidemiological Profile of Patients Initiating Intensive Statin Therapy for the Secondary Prevention of Vascular Disease in Spain].

Rev Esp Salud Publica. 2015 Apr;89(2):159-71. doi: 10.4321/S1135-57272015000200005. Spanish.

Greciano V, Macías Saint-Gerons D, Use of Antihypertensive Drugs in Spain: National Trends From 2000 to 2012.

González-Bermejo D, Montero D, Catalá-López F, de la Fuente Honrubia C.

Rev Esp Cardiol (Engl Ed). 2015 Oct;68(10):899-903. doi: 10.1016/j.rec.2015.06.011. Epub 2015 Aug 8.

Alcalde-Cabero E, Almazán-Isla J, García López FJ, Ara-Callizo JR, Avellanal F, Casanovas C, Cemillán C, Cuadrado JI, Duarte J, Fernández-Pérez MD, Fernández Ó, Merino JA, Montero RG, Montero D, Pardo J, Rodríguez-Rivera FJ, Ruiz-Tovar M, de Pedro-Cuesta J; Spanish GBS Epidemiology Study Group. Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database.

BMC Neurol. 2016 May 21;16:75. doi: 10.1186/s12883-016-0598-z.

de Vries ST, van der Sar MJM, Cupelli A, Baldelli I, Coleman AM, Montero D, Ipi I, Andri A, Wennberg A, Ahlqvist-Rastad J, Denig P, Mol PGM; SCOPE Work Package 6. Communication on Safety of Medicines in Europe: Current Practices and General Practitioners' Awareness and Preferences.

Drug Saf. 2017 Aug;40(8):729-742. doi: 10.1007/s40264-017-0535-0.

Martín Merino E, Huerta Alvarez C, Prieto Alhambra D, Montero Corominas D. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care setting: a population-based cohort study. *Arch Osteopors* 2017; 12:39 DOI 10.1007/s11657-017-0331-6

Radecka A, Loughlin L, Foy M, de Ferraz Guimaraes MV, Sarinic VM, Di Giusti MD, Lesicar M, Straus S, Montero D, Pallos J, Ivanovic J, Raine J. Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action.

Drug Saf. 2018 Aug 21. doi: 10.1007/s40264-018-0708-5. [Epub ahead of print]

Raman SR, Man KKC, Bahmanyar S, Berard A, Bilder S, Boukhris T, Bushnell G, Crystal S, Furu K, KaoYang YH, Karlstad Ø, Kieler H, Kubota K, Lai EC, Martikainen JE, Maura G, Moore N, Montero D, Nakamura H, Neumann A, Pate V, Pottegård A, Pratt NL, Roughead EE, Macias Saint-Gerons D, Stürmer T, Su CC, Zoega H, Sturkenbroom MCJM, Chan EW, Coghill D, Ip P, Wong ICK. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.

Lancet Psychiatry. 2018 Sep 13. pii: S2215-0366(18)30293-1. doi: 10.1016/S2215-0366(18)30293-1. [Epub ahead of print]

Hedenmalm K, Blake K, Donegan K, et al. A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children. Pharmacoepidemiol Drug Saf. 2019;28: 10861096. <https://doi.org/10.1002/pds.4836>

MartinMerino E, LlorenteGarcía A, MonteroCorominas D, Huerta C. The recording of human papillomavirus (HPV) vaccination in BIFAP primary care database: A validation study. Pharmacoepidemiol Drug Saf. 2018;18. <https://doi.org/10.1002/pds.4674>

[Projects](#) ENES-CARE, IMI-PROTECT, SAFEGUARD, SCOPE, ADVANCE, ACCESS

[Memberships](#)

[Other Relevant Information](#)